AI-Based Oxytocin-Stimulated Smart Lactation Support Vest
1 other identifier
interventional
76
0 countries
N/A
Brief Summary
AI-Based Oxytocin-Stimulated Smart Lactation Support Vest: Development of a Thermo-Massage and Vibration Wearable Vest Design to Support Milk Flow and Prevent Milk Duct Obstruction During Lactation
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 10, 2026
CompletedFirst Posted
Study publicly available on registry
August 14, 2026
CompletedStudy Start
First participant enrolled
December 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
Study Completion
Last participant's last visit for all outcomes
May 1, 2028
August 14, 2026
August 1, 2026
1 year
August 10, 2026
August 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Daily Expressed Breast Milk Volume (mL/day)
The amount of breast milk expressed by the mother per day, measured in milliliters (mL/day) during the 10-day follow-up period.
Baseline (Day 0) through Day 10 postpartum
Secondary Outcomes (10)
Maternal Serum Oxytocin Level (pg/mL)
Baseline, Day 5, and Day 10
Maternal Serum Prolactin Level (ng/mL)
Baseline, Day 5, and Day 10
Maternal Serum Cortisol Level (µg/dL)
Baseline, Day 5, and Day 10
Breast Fullness
Day 1 through Day 10
Lactation Onset Symptoms
Day 1 through Day 10
- +5 more secondary outcomes
Study Arms (2)
Arm 1 - Intervention
EXPERIMENTALParticipants assigned to the intervention group will use the AI-based oxytocin-stimulated smart lactation support vest for 10 days, three times daily, in addition to standard lactation care and counseling. Each session will consist of 5 minutes of heating, 15 minutes of heating combined with massage, and 10 minutes of heating combined with massage and vibration. The wearable system is designed to provide controlled thermo-massage and vibration stimulation to support milk flow and lactation during the early postpartum period.
Arm 2 - Control
ACTIVE COMPARATORParticipants assigned to the control group will receive standard lactation care and counseling according to the hospital protocol. Standard care will include routine lactation counseling, guidance regarding breastfeeding and milk expression, breast care, storage of expressed breast milk, daily reminders to express milk, and lactation support when clinically indicated.
Interventions
Participants assigned to the intervention group will use the AI-based oxytocin-stimulated smart lactation support vest for 10 days, three times daily, in addition to standard lactation care and counseling. Each session will consist of 5 minutes of heating, 15 minutes of heating combined with massage, and 10 minutes of heating combined with massage and vibration. The wearable vest is designed to provide controlled thermo-massage and vibration stimulation to support milk flow and lactation during the early postpartum period. The system includes temperature and bioelectrical impedance sensors and an AI-based decision-support module intended to provide individualized recommendations regarding stimulation parameters.
Participants assigned to the control group will receive standard lactation care and counseling according to the hospital protocol. Standard care will include routine lactation counseling, guidance regarding breastfeeding and milk expression, breast care, storage of expressed breast milk, daily reminders to express milk, and lactation support when clinically indicated.
Eligibility Criteria
You may qualify if:
- For Mothers:
- Aged 18 years or older;
- Primiparous;
- Delivered by cesarean section;
- Singleton pregnancy;
- Delivered at 32-37 weeks of gestation;
- Newborn admitted to the Neonatal Intensive Care Unit (NICU);
- No medical condition that would prevent breast milk expression or use of the smart lactation support vest;
- Owns or has access to a smartphone;
- Willing to participate voluntarily and able to provide written informed consent;
- Able to read, understand, and communicate in Turkish.
- For Newborns:
- Born at 32-37 weeks of gestation;
- No condition that would prevent the intake of breast milk.
You may not qualify if:
- For Mothers:
- Body mass index (BMI) \>30 kg/m²;
- History of a psychiatric diagnosis or currently receiving psychiatric treatment (e.g., depression, schizophrenia, obsessive-compulsive disorder);
- Any medical condition that may interfere with breast milk expression (e.g., mastitis);
- Stillbirth;
- History of thyroid dysfunction;
- Any physical condition or disability that prevents wearing the smart lactation support vest;
- Previous breast surgery (e.g., breast implant surgery, mastectomy);
- Insufficient Turkish language proficiency preventing the participant from understanding and completing the study instruments.
- For Newborns:
- Cleft palate or cleft lip;
- Congenital anomaly;
- Requirement for mechanical ventilation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assoc.Prof.
Study Record Dates
First Submitted
August 10, 2026
First Posted
August 14, 2026
Study Start (Estimated)
December 1, 2026
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
May 1, 2028
Last Updated
August 14, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share
Individual participant-level data (IPD) will not be shared with other researchers because the dataset contains potentially sensitive maternal and newborn health information. Data will be retained and managed by the research team in accordance with applicable ethical, institutional, and data protection requirements. De-identified aggregate findings will be reported in scientific publications and presentations.